144 related articles for article (PubMed ID: 25374144)
1. Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type.
Jairam V; Yu JB; Aneja S; Wilson LD; Lloyd S
Am J Clin Oncol; 2017 Jun; 40(3):312-317. PubMed ID: 25374144
[TBL] [Abstract][Full Text] [Related]
2. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.
Ludmir EB; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Mandel JJ; Lin SH; Smith BD; Smith GL; VanderWalde NA; Minsky BD; Koong AC; Stinchcombe TE; Jagsi R; Gomez DR; Thomas CR; Fuller CD
JAMA Oncol; 2019 Dec; 5(12):1769-1773. PubMed ID: 31158272
[TBL] [Abstract][Full Text] [Related]
4. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.
Khan NA; Lombeida JI; Singh M; Spencer HJ; Torralba KD
Arthritis Rheum; 2012 Jul; 64(7):2059-67. PubMed ID: 22275179
[TBL] [Abstract][Full Text] [Related]
5. Does Cancer Literature Reflect Multidisciplinary Practice? A Systematic Review of Oncology Studies in the Medical Literature Over a 20-Year Period.
Holliday EB; Ahmed AA; Yoo SK; Jagsi R; Hoffman KE
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):721-31. PubMed ID: 26104927
[TBL] [Abstract][Full Text] [Related]
6. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Addeo A; Weiss GJ; Gyawali B
JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
[TBL] [Abstract][Full Text] [Related]
7. Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy.
Giacalone NJ; Milani N; Rawal B; Catalano PJ; Nguyen PL; Schoenfeld JD; Tishler RB; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):34-43. PubMed ID: 29970311
[TBL] [Abstract][Full Text] [Related]
8. The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis.
Falk Delgado A; Falk Delgado A
Trials; 2017 Mar; 18(1):125. PubMed ID: 28292317
[TBL] [Abstract][Full Text] [Related]
9. The costs of conducting clinical research.
Emanuel EJ; Schnipper LE; Kamin DY; Levinson J; Lichter AS
J Clin Oncol; 2003 Nov; 21(22):4145-50. PubMed ID: 14559889
[TBL] [Abstract][Full Text] [Related]
10. Influence of study sponsorship on head and neck cancer randomized trial results.
Sun GH; Houlton JJ; MacEachern MP; Bradford CR; Hayward RA
Head Neck; 2013 Oct; 35(10):1515-20. PubMed ID: 22987508
[TBL] [Abstract][Full Text] [Related]
11. Sample size and number of outcome measures of veterinary randomised controlled trials of pharmaceutical interventions funded by different sources, a cross-sectional study.
Wareham KJ; Hyde RM; Grindlay D; Brennan ML; Dean RS
BMC Vet Res; 2017 Oct; 13(1):295. PubMed ID: 28978314
[TBL] [Abstract][Full Text] [Related]
12. Trends in Disclosures of Industry Sponsorship.
Ahmed AA; Holliday EB; Fakhreddine M; Yoo SK; Deville C; Jagsi R
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1093-101. PubMed ID: 27130795
[TBL] [Abstract][Full Text] [Related]
13. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
[TBL] [Abstract][Full Text] [Related]
14. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
[TBL] [Abstract][Full Text] [Related]
15. Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials.
Pang WK; Yeter KC; Torralba KD; Spencer HJ; Khan NA
Int J Rheum Dis; 2015 Jul; 18(6):606-15. PubMed ID: 26012523
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of economic analysis of Radiation Therapy Oncology Group (RTOG) 91-11 using Medicare data.
Konski A; Bhargavan M; Owen J; Paulus R; Cooper J; Forastiere A; Ang KK; Watkins-Bruner D
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):436-42. PubMed ID: 20472371
[TBL] [Abstract][Full Text] [Related]
17. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.
Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD
JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079
[TBL] [Abstract][Full Text] [Related]
18. Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation.
Fundytus A; Wells JC; Sharma S; Hopman WM; Del Paggio JC; Gyawali B; Mukherji D; Hammad N; Pramesh CS; Aggarwal A; Sullivan R; Booth CM
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):28-35. PubMed ID: 34479769
[TBL] [Abstract][Full Text] [Related]
19. Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview.
Janiaud P; Cristea IA; Ioannidis JPA
Intensive Care Med; 2018 Oct; 44(10):1613-1627. PubMed ID: 30151688
[TBL] [Abstract][Full Text] [Related]
20. Primary care research funding sources.
Ruffin MT; Sheets KJ
J Fam Pract; 1992 Sep; 35(3):281-7. PubMed ID: 1517725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
